Welcome

HOPE Research Institute is an independent, multi-specialty, research organization dedicated to conducting clinical research trials in partnership with Valley physicians and their patients.

With NIH certified investigators and ACRP certified study coordinators, HOPE Research Institute can conduct inpatient and outpatient clinical trials across the Phoenix area.

HOPE Research Institute, LLC, conducts clinical research projects for the pharmaceutical industry in the Valley of the Sun, Phoenix, Arizona. Under the careful supervision of trained, experienced physicians, Valley residents can participate in studies of investigational products. HOPE's research facility is conveniently located in North Phoenix on Union Hills Drive near the intersection of freeways 51 and 101. Participants are placed into studies in a variety of therapeutic areas, depending on their eligibility. HOPE's therapeutic ares include: Family / Internal Medicine, Gastroenterology, Neurology / Sleep Medicine, Ophthalmology, Orthopedics / Orthopedic Surgery, Pain Management, Podiatry, Urology, or Women's Health. Study participation can be a positive experience for both the physician and the patient that may provide opportunities for learning, healthcare, and the betterment of our society.

Health and Clinical Research - Latest Headlines

Food and Drug Administration--Press Releases

FDA approves Inlyta to treat patients with a type of advanced kidney cancer - 27 Jan 2012The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
Department of Justice files Consent Decree of Permanent injunction against Ranbaxy - 25 Jan 2012Generic drug manufacturer agrees to remedy deviations from the current good manufacturing practice requirements and to correct data integrity problems at numerous facilities
Maine company holds cold smoked salmon product after FDA order - 24 Jan 2012A Maine food processing and storage company destroyed its cold smoked salmon product under the supervision of the U.S. Food and Drug Administration after inspectors found Listeria monocytogenes within the firm?s facility and on processing equipment
FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri - 20 Jan 2012Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn?s disease (CD).
FDA approves Voraxaze to treat patients with toxic methotrexate levels - 17 Jan 2012The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure. Methotrexate is a commonly used cancer chemotherapy drug normally eliminated from the body by the kidneys. However, patients receiving high doses of methotrexate may develop kidney failure.

National Institutes of Health (NIH) News Releases

New NIH fact sheet explains test for diabetes, prediabetes - 26 Jan 2012A new fact sheet from the National Institutes of Health explains the A1C test, a widely used and important test to diagnose type 2 diabetes and prediabetes, and to monitor blood glucose levels of people with type 1 and type 2 diabetes.
NIH launches trials to evaluate CPR and drugs after sudden cardiac arrest - 26 Jan 2012The National Institutes of Health has launched two multi-site clinical trials to evaluate treatments for out-of-hospital cardiac arrest. One will compare continuous chest compressions (CCC) combined with pause- free rescue breathing to standard cardiopulmonary resuscitation (CPR), which includes a combination of chest compressions and pauses for rescue breathing. The other trial will compare treatment with the drug amiodarone, another drug called lidocaine, or neither medication (a salt-water placebo) in participants with shock-resistant ventricular fibrillation, a condition in which the heart beats chaotically instead of pumping blood.
NIH Study shows caffeine consumption linked to estrogen changes - 26 Jan 2012Asian women who consumed an average of 200 milligrams or more of caffeine a day -- the equivalent of roughly two cups of coffee -- had elevated estrogen levels when compared to women who consumed less, according to a study of reproductive age women by researchers at the National Institutes of Health and other institutions.
Elevated risk factors linked to major cardiovascular disease events across a lifetime - 26 Jan 2012In one of the largest-ever analyses of lifetime risks for cardiovascular disease (CVD), researchers have found that middle-aged adults who have one or more elevated traditional risk factors for CVD, such as high blood pressure, have a substantially greater chance of having a major CVD event, such as heart attack or stroke, during their remaining lifetime than people with optimal levels of risk factors. This National Institutes of Health-supported study used health data from 257,384 people and was the first to look simultaneously at multiple risk factors for CVD across age, sex, race, and birth generation.

World Health Organization News

Dr Margaret Chan nominated for a second term to be WHO Director-General - 18 Jan 201218 January 2012 -- Dr Margaret Chan was nominated today by the WHOs Executive Board for a second term as Director-General of the Organization. If confirmed by the World Health Assembly, Dr Chan's new term will begin on 1 July 2012 and continue until 30 June 2017.
Executive Board appoints the Regional Director for the WHO Eastern Mediterranean Region - 17 Jan 201217 January 2012 -- Dr Ala Alwan will take up his appointment as the Regional Director of WHO's Eastern Mediterranean Region (WHO/EMRO) for a five-year term starting on 1 February 2012.
India records one year without polio cases - 11 Jan 201212 January 2012 -- India appears to have completed one year without polio since its last case on 13 January 2011. This is a momentous achievement because India was once recognized as the world?s epicentre of polio. However, there remains no room for complacency. India must maintain surveillance and high childhood immunity against wild poliovirus until eradication is achieved globally.
WHO recognizes progress of Gulf States for adopting regional strategy to address noncommunicable diseases - 06 Jan 20126 January 2012 -- Six Gulf States detail how they plan to tackle noncommunicable diseases (NCDs) during the coming years. The regional strategy by Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates lays out details on setting targets and measuring results, advancing multisectoral action, and strengthening national capacity to combat NCDs.